Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Kidney Neoplasms 1Hemangiosarcoma 1Glioma 1Glioblastoma 1Congenital Abnormalities 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 109Magnetic Resonance Spectroscopy 52Bevacizumab 52Radiotherapy 44Irinotecan 27Blood Specimen Collection 19Surgical Procedures, Operative 16Radiation 15Aminolevulinic Acid 15Carboplatin 13fluorodopa F 18 12Nivolumab 12Radiotherapy, Intensity-Modulated 11Carmustine 11Radiosurgery 10Magnetic Resonance Imaging 10pembrolizumab 9Topotecan 9Specimen Handling 9Everolimus 9Erlotinib Hydrochloride 9Biopsy 9poly ICLC 8Surveys and Questionnaires 8Standard of Care 8Etoposide 8Drug Therapy 8Lomustine 7Filgrastim 7Cyclophosphamide 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Glioma × trebananib × Clear all
NCT01290263 2017-07-02

Amgen 386 for Recurrent Glioblastoma

Dana-Farber Cancer Institute

Phase 1/2 Completed
48 enrolled 13 charts
CNS

Brain Neoplasms, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡